Report Expects Drug MNCs To Favor China, India Partners
This article was originally published in PharmAsia News
An international report suggests multinational drug makers prefer signing long-term manufacturing contracts with Asian counterparts, particularly in China and India. The Citigroup report said the trend would be to treat Asian companies as partners rather than suppliers or vendors of drugs. The report is based on an annual survey of pharmaceutical and biotechnology companies. The report noted China's WuXi PharmaTech and India's Nicholas Piramal appear to be the most likely companies sought out for those partnerships. Close behind, it named Dishman Pharmaceuticals & Chemicals and Jubilant Organosys, both of India. (Click here for more
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.